AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

ABBV Quantitative Stock Analysis May 20, 2025 — 09:06 am EDT. ... Detailed Analysis of ABBVIE INC. ABBV Guru Analysis. ABBV Fundamental Analysis. More Information on Pim van Vliet.

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

This comprehensive analysis delves into AbbVie’s current position, future prospects, and the factors shaping its stock performance. Company Overview and Recent Performance AbbVie has established ...

AbbVie Inc ABBV released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere ... ABBV Price Action: AbbVie stock is up 1.63% at $212.23 at publication Monday.

AbbVie is expected to post earnings of $3.11 per share for the current quarter, representing a year-over-year change of +17.4%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.3%.